Clinical Drug Supply Chain Services Market Report 2026

The clinical drug supply chain services market size has grown strongly in recent years. It will grow from $8.13 billion in 2025 to $8.94 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to globalization of clinical trials, rising complexity of biologic drugs, stringent regulatory compliance requirements, growth of contract research organizations, expansion of multi-region clinical studies.

The clinical drug supply chain services market size is expected to see rapid growth in the next few years. It will grow to $13.12 billion by 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to ai-enabled predictive supply chain optimization, expansion of decentralized and hybrid clinical trials, rising adoption of real-time supply chain monitoring, growth in personalized medicine and cell and gene therapy trials, increasing automation in clinical logistics operations. Major trends in the forecast period include cold chain optimization for clinical trial logistics, decentralized clinical trial drug distribution models, real-time shipment visibility and tracking in global trials, increased outsourcing to clinical supply specialists, demand for patient-centric investigational drug delivery models.

The rising number of clinical trials is anticipated to propel the growth of the clinical drug supply chain services market going forward. Clinical trials refer to structured and systematically designed research studies conducted on human participants to assess the safety, efficacy, and appropriate dosage of new drugs and medical interventions. The increasing number of clinical trials is primarily driven by growing drug development activities and rising regulatory approvals across advanced healthcare systems, thereby contributing to market expansion. Clinical drug supply chain services support this ecosystem by managing manufacturing, packaging, storage, and distribution processes to ensure timely, compliant, and temperature-controlled delivery of investigational medicines across clinical trial sites. For instance, in December 2024, according to the National Library of Medicine (ClinicalTrials. gov), a US-based government clinical trial registry, the number of registered clinical studies increased from approximately 479,859 studies in January 2024 to over 570,636 studies by December 2024. Therefore, the rising number of clinical trials is driving and supporting the growth of the clinical drug supply chain services market.

Leading companies operating in the clinical drug supply chain services market are focusing on expanding cold chain freight forwarding capabilities, such as state-of-the-art temperature-controlled cross-dock and logistics networks to maintain precise conditions for sensitive pharmaceutical products throughout transit. These capabilities combine strategically located global facilities with integrated monitoring and certification systems to ensure quality and compliance for clinical drug shipments. For example, in August 2025, UPS Healthcare, a US-based logistics and supply chain services provider, expanded its global cold chain freight forwarding network with 20 advanced cross-dock facilities in key cities including Chicago, Singapore, Amsterdam, and Shanghai, featuring refrigerated and controlled room temperature handling, inbound and outbound consolidation with thermal blankets and dry ice support, and multiple certifications such as GDP and IATA CEIV Pharma to enhance package integrity. While regional infrastructure requirements and operational costs remain considerations, these enhancements significantly strengthen precision handling and delivery reliability for clinical drug supply chains worldwide.

In March 2025, DHL Group, a Germany-based logistics and supply chain provider, acquired CRYOPDP for an undisclosed amount. Through this acquisition, DHL aims to enhance its specialty pharma logistics capabilities, expand its clinical trial supply chain services, and strengthen its global position in handling temperature-sensitive and time-critical shipments for biopharmaceutical and clinical research applications. CRYOPDP is a US-based specialty courier company focused on clinical trials, biopharma logistics, and cell and gene therapy supply chain solutions.

Major companies operating in the clinical drug supply chain services market are United Parcel Service Inc., DHL International GmbH, FedEx Corporation, Thermo Fisher Scientific Inc., Kuehne + Nagel International AG, IQVIA Holdings Inc., Yusen Logistics Co. Ltd., ICON Public Limited Company, Lonza Group AG, Catalent Inc., Parexel International Corporation, PCI Services LLC, Almac Group Limited, World Courier Management Inc., Marken Limited, Piramal Pharma Limited, Movianto International GmbH, Clinigen Group plc, Sharp Clinical Services Inc., Biocair International Limited, Ancillare LP, Bilcare Limited, Myonex Inc.

North America was the largest region in the clinical drug supply chain services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clinical drug supply chain services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the clinical drug supply chain services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The clinical drug supply chain services market consists of revenues earned by entities by providing services such as planning, sourcing, labeling, storage, and distribution of clinical trial drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.